Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Holistic treatment for young high-risk multiple myeloma
NCT04008888Phase 2Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib, ixazomib and lenalidomide in multiple myeloma (MM), plasma cell leukemia (PCL) and extramedullary plasmacytoma (EMP) (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
bortezomibixazomiblenalidomide
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)extramedullary plasmacytoma (EMP)
Beyond the preview
Go deeper on NCT04008888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008888.